Meropenem

## Report on Meropenem Package Insert Amendment Regarding Hypokalemia **1. Executive Summary:** This report analyzes a notification from the Central Drugs Standard Control Organization (CDSCO), Directorate General of Health Services, Government of India, dated June 19, 2019. This notification mandates an amendment to the package insert (PI) and promotional literature of Meropenem, a drug approved by CDSCO and marketed in the country. The core purpose is to incorporate Hypokalemia (low potassium levels) as an adverse drug reaction (ADR) based on recommendations from the Pharmacovigilance Programme of India (PvPI) and the Subject Expert Committee (SEC). The key finding is that Meropenem manufacturers are now required to update their product information to include Hypokalemia as a potential side effect, promoting enhanced patient safety through improved prescribing information. **2. Introduction:** This report aims to provide a comprehensive overview of the CDSCO notification F. No. 120118DC Pt337, dated June 19, 2019, concerning Meropenem and Hypokalemia. The analysis is based solely on the provided text of the notification and seeks to inform stakeholders about the implications of this amendment. **3. Policy Overview:** * This notification represents an *amendment* to the existing marketing authorization for Meropenem. * **Core Objective:** To enhance patient safety by incorporating Hypokalemia as a known adverse drug reaction in the prescribing information leaflet (PIL) and promotional literature of Meropenem. **4. Background and Rationale:** This amendment is driven by the identification of Hypokalemia as a potential adverse drug reaction associated with Meropenem use. The National Coordination Centre for Pharmacovigilance Programme of India (NCCPvPI) analyzed ADR reports and, based on Individual Case Study Reports (ICSRs), recommended to CDSCO that Hypokalemia be added to the PIL. The Subject Expert Committee (SEC) on Antimicrobial/Antiviral drugs reviewed and endorsed this recommendation. This process highlights a proactive approach to drug safety, where post-market surveillance data informs changes to product labeling. **5. Key Provisions / Changes:** This section focuses specifically on the changes introduced by this amendment. * **Specific Part of Original Policy Affected:** The pre-existing approval and marketing authorization of Meropenem in India. This amendment impacts the requirements for the package insert and promotional literature of Meropenem. * **New Rule/Provision:** Meropenem manufacturers are now *required* to include Hypokalemia as an adverse drug reaction in the package insert and promotional literature for Meropenem products marketed in India. * **Difference/Effect of This Change:** Previously, the PIL may not have explicitly listed Hypokalemia as a potential ADR. This amendment ensures that healthcare professionals and patients are informed about this risk, allowing for more informed prescribing and monitoring. This change has a direct impact on how prescribers will use meropenem in the future, because they must consider the risk of Hypokalemia. **6. Target Audience and Stakeholders:** The primary target audience and stakeholders directly affected by this amendment are: * Manufacturers of Meropenem formulations marketed in India. They are obligated to update their product information. * State/UT Drugs Controllers: They are tasked with directing the manufacturers under their jurisdiction and reporting back to the CDSCO. * Healthcare professionals (doctors, pharmacists, nurses): They need to be aware of this potential ADR to appropriately prescribe, dispense, and monitor patients taking Meropenem. * Patients taking Meropenem: Increased awareness of Hypokalemia facilitates early detection and management of this potential side effect. **7. Implementation Aspects (Inferred):** * **Responsible Agency/Bodies:** * Central Drugs Standard Control Organization (CDSCO): Responsible for overall implementation and oversight. * State/UT Drugs Controllers: Responsible for directing and monitoring manufacturers within their jurisdiction. * National Coordination Centre for Pharmacovigilance Programme of India (NCCPvPI): Responsible for ADR monitoring and recommendations. * Subject Expert Committee (SEC): Responsible for evaluating recommendations and advising CDSCO. * **Timelines/Procedures:** The notification requests State/UT Drugs Controllers to direct manufacturers and intimate the office regarding the action taken. However, a specific timeline for implementation is not explicitly stated within the provided text. * **Implementation Aspects Related Specifically to the Change:** Manufacturers need to update their package inserts and promotional materials. State/UT drug controllers must ensure this happens. **8. Expected Outcomes / Impact of Changes:** The likely intended outcomes of this amendment are: * **Increased awareness of Hypokalemia as a potential ADR associated with Meropenem among healthcare professionals and patients.** * **Improved monitoring of patients taking Meropenem for signs and symptoms of Hypokalemia.** * **More informed prescribing decisions, potentially leading to adjustments in Meropenem dosage or the use of alternative antibiotics in patients at high risk of Hypokalemia.** * **Overall, enhanced patient safety through better risk management associated with Meropenem use.** **9. Conclusion:** The CDSCO notification mandating the inclusion of Hypokalemia as an ADR in the package insert and promotional literature of Meropenem represents a crucial step in enhancing drug safety. By incorporating this information, healthcare professionals and patients will be better equipped to manage the potential risks associated with Meropenem, ultimately contributing to improved patient outcomes. The active surveillance and feedback loop demonstrated by the PvPI and SEC are vital to maintaining drug safety standards.

Key Entities Referenced